Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study (Q87417591)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Leanne Hodson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Christopher D Byrne

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Lokpal Bhatia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Keith G McCormick

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Geraldine F Clough

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Kathryn Nash

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Helen E Moyses

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Philip C Calder

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

WELCOME Study

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

1 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1211-1221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

10 March 2020

cites work

1 reference

7 January 2021

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

1 reference

7 January 2021

Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

1 reference

7 January 2021

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

1 reference

7 January 2021

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

1 reference

7 January 2021

The epidemiology, pathogenesis and histopathology of fatty liver disease

1 reference

7 January 2021

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

1 reference

7 January 2021

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

1 reference

7 January 2021

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

1 reference

7 January 2021

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

7 January 2021

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

7 January 2021

Effects of thiazolidinediones on bone loss and fracture

1 reference

7 January 2021

Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?

1 reference

7 January 2021

Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease

1 reference

7 January 2021

Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association

1 reference

7 January 2021

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

1 reference

7 January 2021

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]

1 reference

7 January 2021

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

1 reference

7 January 2021

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

7 January 2021

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

7 January 2021

Alcohol consumption and all-cause mortality

1 reference

7 January 2021

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

1 reference

7 January 2021

Current patterns of diet in community-dwelling older men and women: results from the Hertfordshire Cohort Study

1 reference

7 January 2021

Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish.

1 reference

7 January 2021

Low dietary fish-oil threshold for myocardial membrane n-3 PUFA enrichment independent of n-6 PUFA intake in rats

1 reference

7 January 2021

The Omega-3 Index: a new risk factor for death from coronary heart disease?

1 reference

7 January 2021

Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease

1 reference

7 January 2021

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

1 reference

7 January 2021

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

1 reference

7 January 2021

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

1 reference

7 January 2021

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

7 January 2021

Hepatic lipid accumulation in healthy subjects: A comparative study using spectral fat-selective MRI and volume-localized1H-MR spectroscopy

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.27289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25043514%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference